Treatment Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Can adding capecitabine improve outcomes for patients with triple-negative breast cancer?

Posted by on Mar 29, 2020 in Breast cancer | 0 comments

In a nutshell This study looked at adding capecitabine (Xeloda) to standard treatment for patients with triple-negative breast cancer (TNBC). It found that capecitabine improved outcomes for patients with TNBC. Some background Breast tissue growth responds to changing levels of the hormones estrogen and progesterone. Some breast cancer can...

Read More

What are the long-term effects of treatment with a biological drug versus chemotherapy for patients with advanced non-small cell lung carcinoma?

Posted by on Mar 29, 2020 in Lung cancer | 0 comments

In a nutshell This study compared the long-term effects of biological drug pembrolizumab (Keytruda) with chemotherapy drug docetaxel (Taxotere) in patients with advanced non-small cell lung carcinoma (NSCLC). The study found that pembrolizumab increased survival and had fewer side effects than docetaxel. Some background Patients with advanced...

Read More

Which drug improves blood flow and reduces inflammation after stent insertion in patients with heart disease?

Posted by on Mar 28, 2020 in Coronary artery disease | 0 comments

In a nutshell This study compared three drugs to see which was better at improving blood flow and reducing inflammation after patients with heart disease were given a stent. The results showed that prasugrel (Efient) improved patients’ blood flow more than clopidogrel (Plavix) or ticagrelor (Brilique). Some background Heart disease,...

Read More

Which insulin is better for reducing blood glucose levels before hypoglycemia occurs?

Posted by on Mar 28, 2020 in Diabetes mellitus | 0 comments

In a nutshell This study compared two insulin types – degludec (Tresiba) and glargine (Lantus) – to see which was better at reducing blood glucose levels before hypoglycemia (dangerously low blood glucose levels) occurred. The study found that degludec improved blood glucose levels for longer than glargine before patients experienced...

Read More

How did availability of ibrutinib change the treatment of chronic lymphocytic leukemia?

Posted by on Mar 28, 2020 in Leukemia | 0 comments

In a nutshell The study compared treatments in patients with chronic lymphocytic leukemia (CLL), before and after Ibrutinib (Imbruvica) became available in British Columbia, Canada. The authors found that ibrutinib replaced chemoimmunotherapy for treating relapse and improved survival among patients. Some background Chemoimmunotherapy (CIT) was the...

Read More

Monitoring of asparaginase treatments for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Mar 27, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the activity of two types of asparaginase drugs in pediatric patients with acute lymphoblastic leukemia or non-Hodgkin lymphoma. This study concluded that this type of treatment needs close monitoring for optimal effectiveness. Some background Asparaginase (ASNase) is a drug used in the treatment of...

Read More

Monitoring of asparaginase treatments for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Mar 27, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the activity of two types of asparaginase drugs in pediatric patients with acute lymphoblastic leukemia or non-Hodgkin lymphoma. This study concluded that this type of treatment needs close monitoring for optimal effectiveness. Some background Asparaginase (ASNase) is a drug used in the treatment of...

Read More

Evaluating brentuximab vedotin for elderly patients with hard to treat Hodgkin lymphoma

Posted by on Mar 24, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) in elderly patients with relapsed or unresponsive Hodgkin lymphoma (HL). This study found that this treatment was effective, although frail patients may be at higher risk for side effects. Some background Most patients with HL respond to front-line...

Read More

Combining obinutuzumab and chlorambucil in unfit patients with chronic lymphocytic leukemia

Posted by on Mar 24, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness of combining obinutuzumab (Gazyva) and chlorambucil (Leukeran) (O-Clb) to treat physically unfit patients with chronic lymphocytic leukemia (CLL). The authors found that O-Clb is a safe and effective initial treatment for unfit patients with low-risk CLL in a real-world setting. Some background...

Read More

Evaluating the risk of infection associated with ibrutinib treatment in patients with chronic lymphocytic leukemia

Posted by on Mar 20, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as chronic lymphocytic leukemia.  This study concluded that ibrutinib was associated with a higher risk of infections in these patients. Some background B-cell malignancies such as chronic...

Read More